Alabama is currently home to 1237 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Birmingham, Mobile, Huntsville and Anniston. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral Neuropathy
NCT05642611
Recruiting
This phase III trial compares the effect of 3 study approaches in preventing chemotherapy-induced peripheral neuropathy: 1) cryocompression, 2) continuous compression, and 3) low cyclic compression. Taxane chemotherapy drugs, such as paclitaxel or docetaxel, can cause a nerve disorder called peripheral neuropathy, which can cause numbness, tingling, or pain in the arms and legs. The 3 study approaches will use a device, called the Paxman Limb Cryocompression System, made of wraps that cool and/o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/27/2025
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
Conditions: Malignant Solid Neoplasm
Register for Updates
Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases
NCT04711824
Recruiting
This study is a Phase I/II study evaluating the safety and effectiveness of focused radiation therapy (radiosurgery) together with olaparib, followed by immunotherapy, for patients with brain metastases from triple negative or BRCA-mutated breast cancers. This study will have a Phase I portion in which subjects will be enrolled based on 3+3 dose escalation rules. Three dose levels of olaparib will be studied. Cycle 1 of study treatment will consist of Olaparib given twice daily concurrently wi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Breast Cancer, Brain Metastases, Adult
Register for Updates
An INTERNATIONAL, OBSERVATIONAL, BLINDED STUDY to ASSESS the PERFORMANCE of the CORDIO HEARO SYSTEM
NCT06378632
Recruiting
Study Design: This is an international, multicenter, observational, non-interventional, prospective, blinded, single-arm, two-period study, to collect patient utterances that will be retrospectively analyzed to determine the sensitivity and UPNR of the HearO system.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
03/25/2025
Locations: Eastern Shore Research Institute, Fairhope, Alabama
Conditions: Heart Failure
Register for Updates
Pulsed Lavage in Implant-Based Breast Reconstruction
NCT05585710
Recruiting
To determine if there is any benefit to using pulsed lavage to wash out the mastectomy pocket during breast reconstruction. Primary outcomes will include post-op complications including surgical site infection (SSI), hematoma, seroma, and implant failure.
Gender:
FEMALE
Ages:
Between 18 years and 75 years
Trial Updated:
03/25/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Breast Reconstruction
Register for Updates
Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low Weight Infants
NCT05547165
Recruiting
Patent Ductus Arteriosus is a developmental condition commonly observed among preterm infants. It is a condition where the opening between the two major blood vessels leading from the heart fail to close after birth. In the womb, the opening (ductus arteriosus) is the normal part of the circulatory system of the baby, but is expected to close at full term birth. If the opening is tiny, the condition can be self-limiting. If not, medications/surgery are options for treatment. There are two ways... Read More
Gender:
ALL
Ages:
Between 7 days and 32 days
Trial Updated:
03/25/2025
Locations: University of Alabama, Birmingham, Alabama
Conditions: Ductus Arteriosus, Patent
Register for Updates
American Lung Association (ALA) Lung Health Cohort
NCT04543461
Recruiting
The ALA-LHC is a longitudinal, multi-center cohort study that will enroll approximately 4,000 young adults between the ages of 25-35 who do not have severe lung disease. The overarching objective of the ALA-LHC is to establish a national cohort of young adults for the purpose of defining lung health and developing targets to intercept chronic lung disease at its earliest stages.
Gender:
ALL
Ages:
Between 25 years and 35 years
Trial Updated:
03/25/2025
Locations: University Of Alabama, Birmingham, Alabama
Conditions: Lung Diseases
Register for Updates
A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators
NCT06504589
Recruiting
The REACH study is for people with CF who do not take cystic fibrosis transmembrane conductance regulator (CFTR) modulators. The goal of the REACH study is to collect research data, including health data and specimens, from people with CF who do not take CFTR modulators. This data may be used to inform CF research, help design CF clinical trials and support the development of new treatments for people with CF who do not take CFTR modulators. Another goal of this study is to learn about research... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
03/24/2025
Locations: The Children's Hospital Alabama, University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Cystic Fibrosis
Register for Updates
Health Outcomes of Parents With Cystic Fibrosis-Aim 2
NCT06296394
Recruiting
The goal of this observational prospective study is to determine the health impact of parenthood on United States (US) people with CF in the era of CF transmembrane regulator protein (CFTR) modulators. The investigators will collect physical and mental health data to comprehensively evaluate the impact of parenthood in CF with widespread highly effective CFTR modulator use. The main hypotheses this study aims to examine are: H1: Parents with CF and moderate-to-severe depression have more rapid... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: University of Alabama-Birmingham, Birmingham, Alabama
Conditions: Cystic Fibrosis, Parenthood Status
Register for Updates
Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence
NCT05806164
Recruiting
The goal of this clinical trial is to compare treatment outcomes between an oral medication (beta agonist) versus onabotulinumtoxinA injections in women with urgency urinary incontinence (UUI). Participants will be randomly selected to receive one of the two treatments. The primary outcome measure will be at 3 months, and women will be followed for a total of 12 months. Based on patient expert input, there are 2 primary outcomes: Treatment satisfaction and urinary symptom severity.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Urgency Urinary Incontinence
Register for Updates
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
NCT05440708
Recruiting
The primary objectives of Cohort A Phase 1b are to evaluate the safety and tolerability of TTI-101 orally administered as a single agent to participants with locally advanced or metastatic, and unresectable Hepatocellular Carcinoma (HCC) and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of TTI-101 as a single agent. The primary objectives of Cohort A Phase 2 are to evaluate the safety and tolerability of TTI-101 orally administered as a single agent at the... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: The Kirklin Clinic of University of Alabama Birmingham Hospital, Birmingham, Alabama
Conditions: Hepatocellular Carcinoma
Register for Updates
Regulation of Inflammatory Genes in Psoriasis
NCT03125655
Recruiting
Psoriasis is a chronic and recurrent skin disorder characterized by marked inflammatory changes in the skin. An extensive cytokine network including generated by activated dendritic cells and T cells mediates the formation of psoriatic lesions. These immune-response parameters can be used as markers in the severity and management of the disease after further in-depth studies.
Gender:
ALL
Ages:
Between 19 years and 99 years
Trial Updated:
03/24/2025
Locations: The Kirklin Clinic, Birmingham, Alabama
Conditions: Psoriasis, Inflammation
Register for Updates
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
NCT04637763
Recruiting
CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after lymphodepletion consisting of cyclophosphamide and fludarabine.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/21/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non Hodgkin Lymphoma, Lymphoma, B Cell Lymphoma, B Cell Non-Hodgkin's Lymphoma
Register for Updates